Tociliuzumab

PreclinicalMonoclonal antibody

Roche

Tociliuzumab is one of 12 small molecule programs targeting Takayasu arteritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Takayasu ArteritisActive, not recruiting

Takayasu ArteritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Takayasu Arteritis

#DrugCompanyPhaseTrials

Humira

Novartis

Approved

3 2

Cellcept

Roche

Approved

—3

Xeljanz

PPrism Pharmaceuticals

Approved

1 4

Cytoxan

BBaxter Healthcare Corporation

Rayos

Imuran

LLegacy Health System

Rinvoq

1 8

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 9

Arava

Sanofi

Preclinical

2 10

Cimzia

UCB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Takayasu Arteritis

NCT07491913

Clinical

Trials by Indication[1]

Pneumonia1 trial

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

Completed· Roche logo

Roche·Phase 2·NCT04363736·97 enrolled

Takayasu arteritis1 trial

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

Recruiting·MMarmara University·N/A·NCT07491913·40 enrolled

Antisynthetase Syndrome1 trial

Tocilizumab for Refractory Anti-Synthetase Syndrome-Associated Interstitial Lung Disease: A Real-World Retrospective Cohort Study

Completed·HHu Yinan··NCT07662265·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Tociliuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tociliuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tociliuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: Roche

Tociliuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pneumonia1 trial

Takayasu arteritis1 trial

Antisynthetase Syndrome1 trial

References

Drug Info

Quick Facts

Related News